- Home
- AUST vs BOLT Comparison
AUST vs BOLT Comparison
Compare AUST & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUST
- BOLT
- Stock Information
- Founded
- AUST 2020
- BOLT 2015
- Country
- AUST Canada
- BOLT United States
- Employees
- AUST N/A
- BOLT N/A
- Industry
- AUST
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- AUST
- BOLT Health Care
- Exchange
- AUST Nasdaq
- BOLT Nasdaq
- Market Cap
- AUST 19.0M
- BOLT 16.8M
- IPO Year
- AUST 2022
- BOLT 2021
- Fundamental
- Price
- AUST $1.28
- BOLT $5.53
- Analyst Decision
- AUST
- BOLT Buy
- Analyst Count
- AUST 0
- BOLT 3
- Target Price
- AUST N/A
- BOLT $50.00
- AVG Volume (30 Days)
- AUST 53.0K
- BOLT 22.8K
- Earning Date
- AUST 08-11-2025
- BOLT 08-12-2025
- Dividend Yield
- AUST N/A
- BOLT N/A
- EPS Growth
- AUST N/A
- BOLT N/A
- EPS
- AUST N/A
- BOLT N/A
- Revenue
- AUST N/A
- BOLT $3,638,000.00
- Revenue This Year
- AUST N/A
- BOLT N/A
- Revenue Next Year
- AUST N/A
- BOLT $13.62
- P/E Ratio
- AUST N/A
- BOLT N/A
- Revenue Growth
- AUST N/A
- BOLT N/A
- 52 Week Low
- AUST $0.80
- BOLT $5.20
- 52 Week High
- AUST $3.19
- BOLT $14.82
- Technical
- Relative Strength Index (RSI)
- AUST 45.25
- BOLT 40.70
- Support Level
- AUST $1.20
- BOLT $5.50
- Resistance Level
- AUST $1.40
- BOLT $6.14
- Average True Range (ATR)
- AUST 0.07
- BOLT 0.39
- MACD
- AUST -0.01
- BOLT -0.04
- Stochastic Oscillator
- AUST 36.36
- BOLT 14.65
About AUST Austin Gold Corp.
Austin Gold Corp is focused on the acquisition, exploration and evaluation of mineral resource properties in the western United States of America (USA). Exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek in Humboldt County, Lone Mountain and Miller in Elko County, and Stockade Mountain (Oregon).
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.